ClinicalTrials.gg

Program

PORT-77

A development code.

Its studies are mostly in Protoporphyria, Erythropoietic, led by Portal Therapeutics.

Furthest: phase 3, since Aug 25, 20263 company-led studies, 1 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Portal Therapeutics31 open or runningphase 3since Aug 25, 2026Mar 21, 2024Mar 2029phase 3 · NCT07820085

Also a collaborator on its studies: celerion.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 21, 2024First study: phase 1 study in Healthy Adult ParticipantsFirst studyNCT06346509 · 156 enrolled · United States
  2. Apr 3, 2025Phase 2 study in Protoporphyria, ErythropoieticNCT06971900 · 28 enrolled · United States
  3. Aug 25, 2026Phase 3 study in Protoporphyria, ErythropoieticPhase 3 reachedNCT07820085 · 225 planned · United States

Ahead

  1. Mar 2029Primary completion: phase 3 study in Protoporphyria, ErythropoieticNCT07820085

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07820085Protoporphyria, Erythropoietic · United States3RecruitingMar 2029225
NCT06971900Protoporphyria, Erythropoietic · United States2CompletedNov 22, 202528
NCT06346509Healthy Adult Participants · United States1CompletedDec 27, 2025156

How it is read

Names in the registry

  • “PORT-77”, 3 entries

Codes read as this program: PORT77.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.